IMMUNIC, INC. IMUX
Nasdaq · XNAS · stock · Pharmaceutical Preparations
Chart by TradingView
2/9
Piotroski F — financial health
-113.67
Altman Z″ — distress risk · distress
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | — | -$97.2M | — | -$86.0M | -$6.7M |
| 2024 | — | -$100.5M | — | -$85.0M | $18.4M |
| 2023 | — | -$93.6M | — | -$71.2M | $28.9M |
| 2022 | — | -$120.4M | — | -$65.3M | $113.7M |
| 2021 | — | -$92.9M | — | -$83.3M | $127.1M |
| 2020 | — | -$44.0M | — | -$46.3M | $158.8M |
Recent insider activity (Form 4)
| Insider | Role | Date | Action | Shares | Price |
|---|---|---|---|---|---|
| Nash Duane | Executive Chairman | 2025-06-13 | Buy | 20,000 | $0.83 |
Why these scores methodology →
Piotroski F-score: 2/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: -113.67 (distress)
- Working capital / assets -0.322
- Retained earnings / assets -25.302
- EBIT / assets -4.292
- Equity / liabilities -0.217
Source: SEC EDGAR filings · CIK 0001280776 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.